[Mechanism and clinical progress of molecular targeted cancer therapy]

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Molecular target-based cancer therapy is increasingly vital due to its specificity and tolerance.
• Over 50 molecular targeted drugs, including monoclonal antibodies and small molecule kinase inhibitors, have been approved since 1997.
• The development of targeted therapeutics is now a primary strategy in cancer treatment.

Purpose of the Study:

• To review FDA-approved molecular targeted cancer drugs.
• To elucidate the mechanisms of action and clinical applications of these drugs.
• To categorize targeted drugs and identify challenges in molecular targeted therapy.

Main Methods:

• Literature review of FDA-approved molecular targeted drugs.
• Categorization of drugs based on targets: EGFR, antiangiogenesis, specific antigens, and others.
• Analysis of drug mechanisms and clinical utility.

Main Results:

• Summary of approved molecular targeted drugs, detailing their mechanisms and applications.
• Classification into four main categories: EGFR-related, antiangiogenic, specific antigen-related, and other targeted drugs.
• Identification of key characteristics and current status of molecular targeted therapy.

Conclusions:

• Molecular targeted therapy represents a significant advancement in cancer treatment.
• Categorization aids in understanding the diverse landscape of targeted drugs.
• Further research is needed to address existing challenges in molecular targeted therapy.